Site 0241 - Florida Cancer Specialist - North — Lecanto, Florida

Site 0241 - Florida Cancer Specialist - North is a clinical research site located in Lecanto, Florida, United States 34461.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Site 0241 - Florida Cancer Specialist - North has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Sponsors: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Lecanto

Browse all research sites in Florida · View every site in Lecanto

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site 0241 - Florida Cancer Specialist - North?

Site 0241 - Florida Cancer Specialist - North has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site 0241 - Florida Cancer Specialist - North conducted?

Site 0241 - Florida Cancer Specialist - North has 1 clinical trials on record, with 1 currently active. Their work covers High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Is Site 0241 - Florida Cancer Specialist - North accredited by Crixeo Clinical Trials?

Site 0241 - Florida Cancer Specialist - North has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site 0241 - Florida Cancer Specialist - North?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.